Thromboprophylaxis during pregnancy and the puerperium: a systematic review and economic evaluation to estimate the value of future research
Thromboprophylaxe während Schwangerschaft und Wochenbett: systematische Übersicht und ökonomische Bewertung zum Wert künftiger Forschung
Health Technology Assessment · 2024-03 · 1-176
DOI: 10.3310/dfwt3873 ↗Auf einen Blick
Eine systematische Übersicht und Modellanalyse untersuchte die Entscheidungssicherheit zur Thromboprophylaxe in Schwangerschaft und Wochenbett. Die Unsicherheit war beträchtlich, besonders zur Wirksamkeit der Prophylaxe.
Fragestellung
Wie groß ist die Entscheidungunsicherheit bei der Auswahl von Schwangeren und Wöchnerinnen für eine Thromboprophylaxe, und welchen Wert hätten künftige Studien?
Methode
Entscheidungsanalytisches Modell auf Basis einer systematischen Übersicht von Risikobewertungsmodellen; Workshops und Befragung von Gesundheitsfachpersonen; Expected-value-Analysen.
Ergebnisse
Die Übersicht umfasste 17 Studien mit 19 extern validierten und 1 intern validiertem Risikobewertungsmodell. Sensitivität 0 % bis 100 %, Spezifität 5 % bis 100 %; viele Studien mit unklarem oder hohem Biasrisiko.
Einschränkungen
Das Risikomodell für adipöse Wöchnerinnen wurde nicht extern validiert.
Schlussfolgerung der Autor:innen
Künftige Forschung sollte die Wirksamkeit pharmakologischer Thromboprophylaxe in Schwangerschaft und Wochenbett bestimmen; klinische Studien wären bei Frauen ohne frühere venöse Thromboembolie eher akzeptabel.
Kernaussagen
- 17 Studien zu Risikobewertungsmodellen
- Hohe Entscheidungssicherheit besonders unsicher bei Wirksamkeit der Prophylaxe
- RCT bei adipösen Wöchnerinnen vermutlich am wertvollsten
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Systematische Übersicht in der Zeitschrift Health Technology Assessment, 2024-03. Verfasst von Sarah Davis und 10 weiteren Autor:innen. Beteiligte Einrichtung: School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK. Hauptthemen laut MEDLINE: Venous Thromboembolism, Postpartum Period, Cost-Benefit Analysis. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 144 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Health Technology Assessment programme.
Themen: Thromboseprophylaxe
Abstract (Originalsprache)
Background
Pharmacological prophylaxis to prevent venous thromboembolism is currently recommended for women assessed as being at high risk of venous thromboembolism during pregnancy or in the 6 weeks after delivery (the puerperium). The decision to provide thromboprophylaxis involves weighing the benefits, harms and costs, which vary according to the individual’s venous thromboembolism risk. It is unclear whether the United Kingdom’s current risk stratification approach could be improved by further research.
Objectives
To quantify the current decision uncertainty associated with selecting women who are pregnant or in the puerperium for thromboprophylaxis and to estimate the value of one or more potential future studies that would reduce that uncertainty, while being feasible and acceptable to patients and clinicians.
Methods
A decision-analytic model was developed which was informed by a systematic review of risk assessment models to predict venous thromboembolism in women who are pregnant or in the puerperium. Expected value of perfect information analysis was used to determine which factors are associated with high decision uncertainty and should be the target of future research. To find out whether future studies would be acceptable and feasible, we held workshops with women who have experienced a blood clot or have been offered blood-thinning drugs and surveyed healthcare professionals. Expected value of sample information analysis was used to estimate the value of potential future research studies.
Results
The systematic review included 17 studies, comprising 19 unique externally validated risk assessment models and 1 internally validated model. Estimates of sensitivity and specificity were highly variable ranging from 0% to 100% and 5% to 100%, respectively. Most studies had unclear or high risk of bias and applicability concerns. The decision analysis found that there is substantial decision uncertainty regarding the use of risk assessment models to select high-risk women for antepartum prophylaxis and obese postpartum women for postpartum prophylaxis. The main source of decision uncertainty was uncertainty around the effectiveness of thromboprophylaxis for preventing venous thromboembolism in women who are pregnant or in the puerperium. We found that a randomised controlled trial of thromboprophylaxis in obese postpartum women is likely to have substantial value and is more likely to be acceptable and feasible than a trial recruiting women who have had a previous venous thromboembolism. In unselected postpartum women and women following caesarean section, the poor performance of risk assessment models meant that offering prophylaxis based on these models had less favourable cost effectiveness with lower decision uncertainty.
Limitations
The performance of the risk assessment model for obese postpartum women has not been externally validated.
Conclusions
Future research should focus on estimating the efficacy of pharmacological thromboprophylaxis in pregnancy and the puerperium, and clinical trials would be more acceptable in women who have not had a previous venous thromboembolism. Study registration This study is registered as PROSPERO CRD42020221094. Funding This award was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme (NIHR award ref: NIHR131021) and is published in full in Health Technology Assessment ; Vol. 28, No. 9. See the NIHR Funding and Awards website for further award information.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK.
- Women's Health Academic Centre, Guy's and St Thomas' NHS Foundation Trust, London, UK.
- Haematology and Pathology, Guy's and St Thomas' NHS Foundation Trust, London, UK.
- Institute of Population Health Sciences, Queen Mary University of London, London, UK.
- Patient and Public Involvement, Thrombosis UK, Llanwrda, UK.
ORCID-Profile: Sarah Davis, Abdullah Pandor, Fiona C Sampson, Jean Hamilton, Catherine Nelson-Piercy, Beverley J Hunt, Jahnavi Daru, Steve Goodacre, Rosie Carser, Gill Rooney, Mark Clowes
Förderung
- Health Technology Assessment programme
Zitieren
APA
Davis, S., Pandor, A., Sampson, F. C., Hamilton, J., Nelson-Piercy, C., Hunt, B. J., Daru, J., Goodacre, S., Carser, R., Rooney, G., & Clowes, M. (2024). Thromboprophylaxis during pregnancy and the puerperium: a systematic review and economic evaluation to estimate the value of future research. Health Technology Assessment, 1-176. https://doi.org/10.3310/dfwt3873
Vancouver
Davis S, Pandor A, Sampson FC, Hamilton J, Nelson-Piercy C, Hunt BJ, et al. Thromboprophylaxis during pregnancy and the puerperium: a systematic review and economic evaluation to estimate the value of future research. Health Technology Assessment. 2024:1-176. doi:10.3310/dfwt3873
BibTeX
@article{Davis2024,
author = {Davis, Sarah and Pandor, Abdullah and Sampson, Fiona C and Hamilton, Jean and Nelson-Piercy, Catherine and Hunt, Beverley J and Daru, Jahnavi and Goodacre, Steve and Carser, Rosie and Rooney, Gill and Clowes, Mark},
title = {Thromboprophylaxis during pregnancy and the puerperium: a systematic review and economic evaluation to estimate the value of future research},
journal = {Health Technology Assessment},
year = {2024},
pages = {1--176},
doi = {10.3310/dfwt3873}
}
EUVIMED